Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics, Inc. (PSTV) has completed dosing in Cohort 4 of the ReSPECT-LM Phase 1/2a clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from solid tumors. The company has also completed the transfer of proprietary materials, protocols, and equipment from Biocept under the terms of the recently announced expanded agreement for CNSide.
October 10, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics has completed a significant phase of its clinical trial and a transfer of proprietary materials from Biocept. This could potentially accelerate the development of its treatment for leptomeningeal metastases.
The completion of dosing in Cohort 4 of the ReSPECT-LM Phase 1/2a clinical trial and the transfer of proprietary materials from Biocept are significant steps in Plus Therapeutics' development of its treatment for leptomeningeal metastases. This could potentially lead to faster progress in the trial and a positive impact on the company's stock.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100